Lung Carcinoma — Trials

Lung Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,130
Recruiting: 1,129
Ph III recruiting: 164
Growth YoY: +0.2%
Industry share: 43%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.7%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,179)

clinicaltrialsPublishedShowing 351–400 of 1,132 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07314216	Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma	recruiting	Phase 2	15	Hunan Cancer HospitalOTHER	1	Jul 8, 2026	clinicaltrials
NCT06268210	Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(NeoLazer)	active not recruiting	Phase 2	160	Yonsei UniversityOTHER	1	Jul 7, 2026